Catalyst-dependent drug loading of LDI-glycerol polyurethane foams leads to differing controlled release profiles

Acta Biomaterialia

Volumn 4, Issue 5, 2008, Pages 1263-1274

  Sivak, Wesley N ^a,b   Pollack, Ian F ^b,c   Petoud, Stéphane ^d   Zamboni, William C ^b,d   Zhang, Jianying ^a   Beckman, Eric J ^a  

^a University of Pittsburgh   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Camptothecin; Drug delivery; Glioma; Lysine diisocyanate; Polyurethane

Indexed keywords

AMINO ACIDS; BIOCOMPATIBILITY; CATALYSTS; CELL CULTURE; CELL PROLIFERATION; CONTROLLED DRUG DELIVERY; ESTERS; FLUORESCENCE MICROSCOPY; GLYCEROL; SCANNING ELECTRON MICROSCOPY; TARGETED DRUG DELIVERY; TUMORS;

CAMPTOTHECINS; CELLULAR PROLIFERATIONS; CONTROLLED RELEASE; DRUG LOADING; DRUG-DELIVERY SYSTEMS; GLIOMA CELL LINES; LYSINE DIISOCYANATE; POLYURETHANE FOAM; RELEASE PROFILES; ]+ CATALYST;

POLYURETHANES;

1,4 DIAZABICYCLO[2.2.2]OCTANE; 4,4' (OXYDI 2,1 ETHANEDIYL)BISMORPHOLINE; 7 TERT BUTYLDIMETHYLSILYL 10 HYDROXY CAMPTOTHECIN; AMINE; CAMPTOTHECIN DERIVATIVE; DB 67; DRUG CARRIER; GLYCEROL; LYSINE DIISOCYANATE; POLYURETHAN FOAM; URETHAN;

ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CANCER CELL CULTURE; CANCER INHIBITION; CATALYST; CELL PROLIFERATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG RELEASE; DRUG STRUCTURE; FLUORESCENCE MICROSCOPY; GLIOMA; HIGH TEMPERATURE; HUMAN; HUMAN CELL; IN VITRO STUDY; MORPHOLOGY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SYNTHESIS;

EID: 48449101459     PISSN: 17427061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actbio.2008.01.008     Document Type: Article

References (36)

1. Hatefi A., and Amsden B. Camptothecin delivery methods. Pharm Res 19 10 (2002) 1389-1399
2. Pommier Y., Pourquier P., Urasaki Y., Wu J., and Laco G.S. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 2 5 (1999) 307-318
3. Jung L.L., and Zamboni W.C. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?. Drug Resist Updat 4 4 (2001) 273-288
4. Li Q.-Y., Zu Y.-G., Shi R.-Z., and Yao L.-P. Review camptothecin: current perspectives. Curr Med Chem 13 17 (2006) 2021-2039
5. Wall M.E., Wani M.C., Cook C.E., Palmer K.H., McPhail A.T., and Sim G.A. Plant antitumor agents. I. Isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88 16 (1966) 3888-3890
6. Hsiang Y.H., et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49 16 (1989) 4385-4389
7. Hsiang Y.H., Lihou M.G., and Liu L.F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49 18 (1989) 5077-5082
8. Bom D., et al. Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities. J Med Chem 42 16 (1999) 3018-3022
9. Bom D., et al. The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. J Med Chem 43 21 (2000) 3970-3980
10. Bom D., et al. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J Control Release 74 1-3 (2001) 325-333
11. Mi Z., and Burke T.G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 33 34 (1994) 10325-10336
12. Hinrichsen G. In: Oertel G. (Ed). Polyurethane handbook. 2nd ed. (1993), Hanser, Munich
13. Guelcher S.A. Polyurethanes. Introduction to biomaterials (2005), CRC Press p. 161-83.
14. Walder A.J. Characteristics of medical polyurethanes. Plast Eng (Brookfield, Connecticut) 54 4 (1998) 29-31
15. Szycher M., Siciliano A.A., and Reed A.M. Polyurethane elastomers in medicine. Polym Biomater (1994) 233-244
16. Hasirci N. Polyurethanes. High Perform Biomater (1991) 71-90
17. Gogolewski S. Selected topics in biomedical polyurethanes. A review. Colloid Polym Sci 267 9 (1989) 757-785
18. Guelcher S., et al. Synthesis, in vitro degradation, and mechanical properties of two-component poly(ester urethane)urea scaffolds: effects of water and polyol composition. Tissue Eng 13 9 (2007) 2321-2333
19. Guelcher S.A., et al. Synthesis and in vitro biocompatibility of injectable polyurethane foam scaffolds. Tissue Eng 12 5 (2006) 1247-1259
20. Vratsanos M. Polyurethane catalysts. In: Salamone J.C. (Ed). Polymeric materials encyclopedia (1996), CRC Press, New York 6947-6957
21. Silva A.L., and Bordado J.C. Recent developments in polyurethane catalysis: catalytic mechanisms review. Catal Rev Sci Eng 46 1 (2004) 31-51
22. Lee S.-H., Kim S.-R., Kim J.S., Bae H.-R., Lee C.-H., and Kim D.-D. In-vitro and in-vivo antibacterial activity evaluation of a polyurethane matrix. J Pharm Pharmacol 55 4 (2003) 559-566
23. Park J.H., Lee K.B., Kwon I.C., and Bae Y.H. PDMS-based polyurethanes with MPEG grafts: mechanical properties, bacterial repellency, and release behavior of rifampicin. J Biomater Sci Polym Ed 12 6 (2001) 629-645
24. Yamaoka T., Makita Y., Sasatani H., Kim S.I., and Kimura Y. Linear type azo-containing polyurethane as drug-coating material for colon-specific delivery: its properties, degradation behavior, and utilization for drug formulation. J Control Release 66 2-3 (2000) 187-197
25. Ouchi T., Hagihara Y., Takahashi K., Takano Y., and Igarashi I. Synthesis and antitumor activity of poly(ethylene glycol)s linked to 5-fluorouracil via a urethane or urea bond. Drug Des Discover 9 1 (1992) 93-105
26. Zhang J.Y., Beckman E.J., Piesco N.P., and Agarwal S. A new peptide-based urethane polymer: synthesis, biodegradation, and potential to support cell growth in vitro. Biomaterials 21 12 (2000) 1247-1258
27. Zhang J.Y., Beckman E.J., Hu J., Yang G.G., Agarwal S., and Hollinger J.O. Synthesis, biodegradability, and biocompatibility of lysine diisocyanate-glucose polymers. Tissue Eng 8 5 (2002) 771-785
28. Sivak W.N., Pollack I.F., Petoud S., Zamboni W.C., Zhang J., and Beckman E.J. LDI-glycerol polyurethane implants exhibit controlled release of DB-67 and anti-tumor activity in vitro against malignant gliomas. Acta Biomater (2007) [in review]
29. Pollack I.F., Erff M., Bom D., Burke T.G., Strode J.T., and Curran D.P. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo. Cancer Res 59 19 (1999) 4898-4905
30. Huang S.J., Wang J.M., Tseng S.C., Wang L.F., and Chen J.S. Controlled immobilization of chondroitin sulfate in polyacrylic acid networks. J Biomater Sci Polym Ed 18 1 (2007) 17-34
31. Jaeger R.J., Plugge H., and Szabo S. Acute urinary bladder toxicity of a polyurethane foam catalyst mixture: a possible new target organ for a propionitrile derivative. J Environ Pathol Toxicol 4 2-3 (1980) 555-562
32. Gad S.C. A neuromuscular screen for use in industrial toxicology. J Toxicol Environ Health 9 5-6 (1982) 691-704
33. Luo Y., and Prestwich G.D. Cancer-targeted polymeric drugs. Curr Cancer Drug Targets 2 3 (2002) 209-226
34. Artavia L.D., and Macosko C.W. Polyurethane flexible foam formation. Low Density Cell Plast (1994) 22-55
35. Hartley F.D., Cross M.M., and Lord F.W. Mechanism of polyurethane foam formation. Adv Polyurethane Technol (1968) 127-140
36. Burke T.G., Mishra A.K., Wani M.C., and Wall M.E. Lipid bilayer partitioning and stability of camptothecin drugs. Biochemistry 32 20 (1993) 5352-5364